Patents by Inventor Craig Fenwick
Craig Fenwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230393135Abstract: The invention provides an in vitro method for the cell-free quantification of virus neutralizing activity, such as the SARS-CoV-2 neutralizing activity, of biological samples and kit for carrying out the method. The invention also provides a method of screening biological samples or collections of molecules to identify neutralizing antibodies or antiviral drugs.Type: ApplicationFiled: November 2, 2021Publication date: December 7, 2023Inventors: Didier TRONO, Priscilla TURELLI, Giuseppe PANTALEO, Craig FENWICK
-
Publication number: 20230034677Abstract: The inventors now provide novel IL-15/IL-15 receptor alpha (IL-15R?) fusion proteins. Furthermore, as a complement to anti-PD-1 therapy, the inventors developed a series of anti-PD-1/IL-15/IL-15 receptor alpha (IL-15R?) immunocytokines that are able to simultaneously target multiple steps in the immune activation process. The development of said immunocytokines provides the potential benefits associated with anti-PD-1 antibodies and IL-15 administered individually with several distinct advantages. These include a significantly extended in vivo half-life relative to the IL-15 therapy, administration of a pre-formed IL-15/IL-15R? complex that would preclude the need for IL-15R? trans-presentation, high activity leading to a low target therapeutic dose and targeted delivery of IL-15 to regions with high PD-1 cells that will limit off-target adverse events.Type: ApplicationFiled: November 20, 2020Publication date: February 2, 2023Inventors: Yves LEVY, Giuseppe PANTALEO, Craig FENWICK, Sandra ZURAWSKI, Gérard ZURAWSKI, Nabila SEDDIKI
-
Publication number: 20220267416Abstract: This disclosure relates to LN02M binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS. In some embodiments, this disclosure provides a binding agent(s) comprising a variable region shown in FIGS. 6A through 6E; amino acid sequence of any mutant of FIGS. 7A through 7D and/or FIGS. 8A through 8F, and any effective (e.g., HIV neutralization) combination thereof; any one or more of SEQ ID NOS. 3-92, 95-233, 248-482, or 491-699; and/or combinations thereof.Type: ApplicationFiled: July 15, 2020Publication date: August 25, 2022Applicant: Lausanne University HospitalInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20220259315Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: ApplicationFiled: January 3, 2022Publication date: August 18, 2022Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20220169733Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.Type: ApplicationFiled: September 27, 2021Publication date: June 2, 2022Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Patent number: 11214617Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: GrantFiled: May 17, 2018Date of Patent: January 4, 2022Assignee: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Patent number: 11130807Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.Type: GrantFiled: May 17, 2018Date of Patent: September 28, 2021Assignee: MabQuest, S.A.Inventors: Giuseppe Pantaleo, Craig Fenwick
-
Patent number: 10294299Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: GrantFiled: January 20, 2017Date of Patent: May 21, 2019Assignee: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20190106493Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.Type: ApplicationFiled: May 17, 2018Publication date: April 11, 2019Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20190062431Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: ApplicationFiled: May 17, 2018Publication date: February 28, 2019Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20180265582Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: ApplicationFiled: January 20, 2017Publication date: September 20, 2018Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Patent number: 9982053Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.Type: GrantFiled: August 5, 2015Date of Patent: May 29, 2018Assignee: MabQuest, SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Patent number: 9982052Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: GrantFiled: September 22, 2016Date of Patent: May 29, 2018Assignee: MabQuest, SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20170226210Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.Type: ApplicationFiled: August 5, 2015Publication date: August 10, 2017Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20170166642Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: ApplicationFiled: September 22, 2016Publication date: June 15, 2017Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Patent number: 7939545Abstract: Compounds of formula I: wherein a, b, c, X, R2, R3, R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: May 9, 2007Date of Patent: May 10, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Youla S. Tsantrizos, Michael Boes, Christian Brochu, Craig Fenwick, Stephen Mason, Marc Pesant, Eric Malenfant
-
Publication number: 20080221159Abstract: Compounds of formula I: wherein a, b, c, X, R2, R3, R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: May 9, 2007Publication date: September 11, 2008Inventors: Youla S. TSANTRIZOS, Michael BOES, Christian BROCHU, Craig FENWICK, Stephen MASON, Marc PESANT, Eric MALENFANT